October 23, 2024Current Cardiology ReportsOpen Access

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors

View Full Paper

Ask AI

Bookmark

Why the study?

This review was conducted to detail significant advancements in knowledge regarding immune-checkpoint inhibitors and their potential deleterious cardiac immune-related adverse effects, mechanisms, risk factors, clinical presentations, diagnostic strategies, and treatment.

Design

Review

Authors

MGMaría T. GameroAlbert Einstein College of Medicine ESEugene StorozynskyThomas Jefferson University

Discussion

Member takes

Implication

Alerts clinicians to ICI cardiac irAEs beyond myocarditis; extends the evidence base for risk assessment and management.

Structured PICO

Population

Patients with malignancy receiving immune checkpoint inhibitor therapy

Intervention

Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1, LAG-3)

This review summarizes the mechanisms, risk factors, and clinical management of cardiac immune-related adverse events associated with immune checkpoint inhibitors, emphasizing the need for multidisciplinary care and routine monitoring.

Cite This Study

Gamero et al. (2024) studied this question.

synapsesocial.com/papers/6a7d074fb0b0e582d537cb93 https://doi.org/10.1007/s11886-024-02147-x

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark